Inactive Instrument

News Acasti Pharma Inc Toronto S.E.

Equities

APO

CA00430K1057

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

Feb. 12	Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
Feb. 07	Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	Feb. 12	AQ
Acasti: Fiscal Q3 Earnings Snapshot	Feb. 12	AQ
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target	Feb. 07	MT
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	Feb. 01	AQ
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	Feb. 01	CI
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	Jan. 08	CI
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	Dec. 13	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 14	AQ
Acasti: Fiscal Q2 Earnings Snapshot	Nov. 13	AQ
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	Nov. 13	AQ
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	23-10-24	MT
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	23-10-24	AQ
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial	23-10-23	AQ
Acasti Pharma Inc. Announces Board Changes	23-10-11	CI
Transcript : Acasti Pharma Inc. - Special Call	23-10-11
Transcript : Acasti Pharma Inc. - Shareholder/Analyst Call	23-10-10
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage	23-10-05	AQ
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)	23-10-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Acasti Pharma Inc Toronto S.E.

Equities

APO

CA00430K1057

Summary

Filters